Unplanned discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia

Author：          

Publisher： Science Publishers

ISSN： 2049-9450

Source： Molecular and Clinical Oncology, Vol.4, Iss.1, 2016-01, pp. : 89-92

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 8, 2009-10 ,pp. : 853-863

Bentham Science Publishers

Access to resources Recommend Favorite

Chronic Myeloid Leukemia: The Value of Tyrosine Kinase Inhibition

By Tariq I. Mughal   John M. Goldman  

American Journal of Cancer, Vol. 2, Iss. 5, 2003-01 ,pp. : 305-311

Adis International

Access to resources Recommend Favorite

Tyrosine kinase inhibition in acute myeloid leukemia

By Altman Jessica K.   Szilard Amy K.   Platanias Leonidas C.  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1351-1352

Informa Healthcare

Access to resources Recommend Favorite

Membrane Tyrosine Kinase Receptors are an Important Target for the Therapy of Acute Myeloid Leukemia

By  

Current Cancer Therapy Reviews, Vol. 4, Iss. 1, 2008-02 ,pp. : 31-49

Bentham Science Publishers

Access to resources Recommend Favorite

Switching to second‐generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib‐treated patients with chronic myeloid leukemia with more than 10% of BCR‐ABL/ABL ratio at 3 months

By  

Cancer Medicine, Vol. 4, Iss. 7, 2015-07 ,pp. : 995-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite